Health-Related Quality of Life and Its Determinants in Chronic Cough: The Korean Chronic Cough Registry Study

Kang, Noeul; Won, Ha-Kyeong; Lee, Ji‐Hyang; Shim, Ji-Su; Kang, Sung Yoon; Park, Han Ki; Jo, Eun-Jung; Lee, Seung Eun; Kim, Min-Hye; Kim, Sang‐Heon; Kim, Sae‐Hoon; Chang, Yoon-Seok; Lee, Byung-Jae; Song, Woo Jung; Jo, Min‐Woo

doi:10.4168/aair.2023.15.3.348

Cited by 9 publications

(3 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The level of HRQOL among healthy people was reported as 0.96±0.08 [ 38 ], and that among people with chronic conditions was reported as 0.64±0.31 [ 39 ]. In our study conducted on community-dwelling older adults aged 70–84 y, the mean HRQOL score was 0.84±0.10, lower than that among healthy people but higher than that among people with chronic conditions.…”

Section: Discussionmentioning

confidence: 99%

Mediating role of health literacy in relationship between frailty and health-related quality of life in community-dwelling older adults

Kim,

Kim

2024

PLoS ONE

View full text Add to dashboard Cite

Purpose The aim of this study was to investigate the mediating effects of health literacy on the relationship between frailty and health-related quality of life (HRQOL) among community-dwelling older adults. Methods This study used the Korean Frailty and Aging Cohort Database (KFACD) for secondary data analysis. We selected data from 1,631 people without missing main variable values for analysis. Frailty was determined based on the modified Fried’s phenotype [MFP], and HRQOL was measured using the Korean version of the 5-level EuroQol questionnaire (EQ-5D-5L). Health literacy was assessed using the questions on the Behavioral Risk Factor Surveillance System (BRFSS) used by the U.S. Center for Disease Control and Prevention. To examine the mediating role of health literacy in the relationship between frailty and HRQOL, Baron & Kenny’s three-step mediating effect verification method was utilized. Results The participants had a mean frailty score of 1.37±1.02, health literacy score of 8.56±2.59, and HRQOL score of 0.84±0.10. Frailty was negatively correlated with health literacy (r = -0.27, p < .001) and HRQOL (r = -0.32, p < .001), while health literacy was positively correlated with HRQOL (r = 0.34, p < .001). We observed that health literacy played a partial mediating role in the relationship between frailty and HRQOL. Conclusion To increase older adults’ HRQOL, measures that directly prevent and manage frailty as well as interventions that target the enhancement of health literacy are needed.

show abstract

Section: Discussionmentioning

confidence: 99%

Mediating role of health literacy in relationship between frailty and health-related quality of life in community-dwelling older adults

Kim,

Kim

2024

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…Chronic cough, persisting for more than 8 weeks, is prevalent in the general adult population and significantly impacts quality of life (QoL) [5][6][7][8][9][10].…”

Section: Introductionmentioning

confidence: 99%

Could cough hypersensitivity symptom profile differentiate phenotypes of chronic cough?

Kim,

Won,

et al. 2024

ERJ Open Res

View full text Add to dashboard Cite

The symptoms of cough hypersensitivity do not distinguish between asthmatic cough and refractory chronic cough. Cough reflex hypersensitivity may underlie chronic cough across different phenotypes, despite having different treatable traits,BackgroundRecently, cough reflex hypersensitivity has been proposed as a common underlying feature of chronic cough in adults. However, symptoms and clinical characteristics of cough hypersensitivity have not been studied amongst phenotypes of chronic cough. This study aimed to compare symptom features, such as cough triggers and associated throat sensations, of cough hypersensitivity in patients with asthmatic chronic cough and those with refractory chronic cough (RCC).MethodsPatients with chronic cough from the Korean Chronic Cough Registry were prospectively evaluated over 6 months. Physicians determined the etiological diagnosis based on clinical evaluations and responses to treatment at the 6-month follow-up visit. Symptoms of cough hypersensitivity and cough-specific quality of life were assessed using the Cough Hypersensitivity Questionnaire (CHQ) and the Leicester Cough Questionnaire (LCQ), respectively.ResultsThe analysis included 280 patients who completed the follow-up: 79 with asthmatic cough (cough variant asthma or eosinophilic bronchitis) and 201 with RCC. Baseline CHQ scores were similar between the groups (8.3±3.7 in asthmatic coughversus8.9±3.9 in RCC; p=0.215, adjusted for age, sex and and LCQ score). There were no significant between-group differences in the LCQ and cough severity VAS scores. Both groups showed a similar negative correlation with LCQ scores (asthmatic cough: r=−0.427, p<0.001; RUCC: r=−0.306, p<0.001).ConclusionsThe symptoms of cough hypersensitivity may not distinguish between asthmatic cough and RCC. This suggests that chronic cough is the primary diagnosis in both phenotypes. It indicates a shared mechanism in their cough pathogenesis, despite having potentially different treatable traits.

show abstract

“…Chronic cough is a common medical condition with a prevalence of 5-10% in general populations [1]. It is a major cause of morbidity and impairs patient quality of life (QoL) [2][3][4].…”

Section: Introductionmentioning

confidence: 99%

Effects of bepotastine, a nonsedating H1-antihistamine, for the treatment of persistent cough and allergic rhinitis: a randomised, double-blind, placebo-controlled trial

Lee,

Oh,

Kwon

et al. 2023

ERJ Open Res

Self Cite

View full text Add to dashboard Cite

BackgroundEmpirical therapy with oral histamine-1 receptor antagonists (H1RAs) is often used for patients with suspected upper airway cough syndrome. No placebo-controlled trials with non-sedating H1RAs (nsH1RAs) have evaluated validated cough outcomes.ObjectiveTo assess the effect of an nsH1RA, bepotastine, on cough outcomes in patients with allergic rhinitis (AR) and persistent cough.MethodsA randomized, double-blind, placebo-controlled trial was conducted. Adult patients with persistent cough (>3 weeks in duration) and symptomatic AR were recruited and randomly assigned to receive either bepotastine or placebo at a 1:1 ratio. The primary outcome was cough-specific quality of life assessed by the Leicester Cough Questionnaire (LCQ). Secondary outcomes included cough severity visual analog scale (VAS), throat VAS, Cough Hypersensitivity Questionnaire, Sinonasal Outcome Test-22 score, and drug adverse events.ResultsBetween October 2021 and September 2022, 50 participants (43 females; mean age: 46.28 years; median cough duration: 3 months) were assigned to either the bepotastine 10 mg twice daily or placebo group in a 1:1 ratio. After two weeks of treatment, both bepotastine and placebo groups showed significant improvements in the LCQ scores, but there was no significant difference in the magnitude of change between the groups (3.45±2.10versus3.04±2.94, p=0.576). Secondary outcomes were also comparable.ConclusionsDespite the relatively small sample size, our study clearly demonstrated that a two-week treatment with bepotastine did not provide therapeutic benefits for cough outcomes. These findings suggest against the use of nsH1RAs with the intention of improving cough outcomes even in patients with persistent cough and AR.

show abstract

Health-Related Quality of Life and Its Determinants in Chronic Cough: The Korean Chronic Cough Registry Study

Cited by 9 publications

References 39 publications

Mediating role of health literacy in relationship between frailty and health-related quality of life in community-dwelling older adults

Mediating role of health literacy in relationship between frailty and health-related quality of life in community-dwelling older adults

Could cough hypersensitivity symptom profile differentiate phenotypes of chronic cough?

Effects of bepotastine, a nonsedating H1-antihistamine, for the treatment of persistent cough and allergic rhinitis: a randomised, double-blind, placebo-controlled trial

Contact Info

Product

Resources

About